-
NMPA Announcement on Guidance for the Classification Defining of AI-Based Medical Software Products
2021-07-08
The NMPA has organized to formulate the Principles for the Classification Defining of AI-Based Medical Software Products, which was issued on July 1.
-
NMPA Announcement on the Revision of the Package Insert of Metoclopramide
2021-07-05
In accordance with the results of adverse drug reaction evaluation, to further protect drug safety for the people, the NMPA decided to modify the items of [Adverse reactions], [Contraindications] and [Precautions] in the package inserts of Metoclopramide.
-
NMPA Announcement on Issuing 2 Guidance including the Technical Review Guidance for the Registration of Vision Screeners and Mammography Systems
2021-06-29
The NMPA organized to formulation of the Guidelines for Technical Review of Vision Screener Registration and the Guidelines for Technical Review of Mammography System Registration, which were published on June 24.
-
NMPA Announcement on the Revision of the Package Insert of Somatostatin for Injection
2021-06-24
The NMPA decided to modify the items of [Adverse reactions],[Precautions] and [Drug Interactions] in the package inserts of somatostatin for injection.
-
NMPA Announcement on the Revision of the Package Insert of the Oxiracetam Preparations
2021-06-24
The NMPA decided to modify the items of [Adverse reactions], [Contraindications] and [Precautions] in the package inserts of oxiracetam preparations. On June 22, relevant issues are hereby announced as follows.
-
Announcement of NMPA and General Administration of Customs on the Establishment of Changchun Airport as a Drug Import Port
2021-06-15
According to the Drug Administration Law of the People's Republic of China, upon approval of the State Council, NMPA and General Administration of Customs agree to establish Changchun Airport as a drug import port.
